CWC Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

CWC Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$874K	Buy	5,540 +41	+0.7%	+$6.47K	0.41%	62
2026 Q2	$870K	Sell	5,499 -131	-2%	-$17.7K	0.39%	64
2026 Q1	$719K	Sell	5,630 -61	-1%	-$7.62K	0.34%	70
2025 Q4	$694K	Sell	5,691 -16	-0.3%	-$1.84K	0.34%	70
2025 Q3	$572K	Buy	5,707 +157	+3%	+$14.1K	0.28%	82
2025 Q2	$460K	Buy	5,550 +183	+3%	+$14.6K	0.24%	88
2025 Q1	$435K	Buy	5,367 +1,919	+56%	+$172K	0.25%	86
2024 Q4	$311K	Buy	3,448 +67	+2%	+$6.49K	0.31%	87
2024 Q3	$334K	Buy	+3,381	New	+$332K	0.33%	82

Other funds holding XBI

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return

MIRAE ASSET SECURITIES (USA) INC. New York $3.57B AUM 26.72% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Parkway Wealth Management Plano, Texas $869M AUM 25.74% 1-Year Est. Return

Weatherly Asset Management Del Mar, California $1.42B AUM 33.31% 1-Year Est. Return

L. Roy Papp & Associates Phoenix, Arizona $981M AUM 26.21% 1-Year Est. Return

Madrona Financial Services Everett, Washington $646M AUM 23.24% 1-Year Est. Return

Royal Fund Management Lady Lake, Florida $1.26B AUM 23.83% 1-Year Est. Return

Edge Wealth Management New York $666M AUM 17.64% 1-Year Est. Return

CWC Advisors's XBI Position: Q3 2026 in Review

CWC Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.75% in Q3 2026, buying an estimated $6.47K and bringing the position to 5,540 shares worth $874K. The position accounts for 0.41% of the portfolio, ranked #62.

CWC Advisors first reported a position in XBI in Q3 2024 and has held it in 9 quarters since. 307 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

CWC Advisors held 5,540 shares of State Street SPDR S&P Biotech ETF worth $874K as of Q3 2026.
CWC Advisors bought 41 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $6.47K.
State Street SPDR S&P Biotech ETF made up 0.41% of CWC Advisors's portfolio in Q3 2026, its #62 holding.
CWC Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2024 and has held it in 9 quarters since.
307 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on CWC Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.